Abstract #0145

Immune Checkpoint Blockade (ICB) Response Evaluation with MRI/MR Elastography (MRE) in Surgical and Non-Surgical Patients with HCC

Aliya Qayyum¹, Rony Avritscher², Rizwan Aslam¹, Jingfei Ma³, Mark Pagel⁴, Jia Sun⁵, Yehia Ibrahim Mohammed⁶, Manal Hassan⁷, Hesham Amin⁸, Asif Rashid⁹, Sunyoung Lee⁶, Robert A Wolff⁶, James C Yao⁶, Richard L Ehman¹⁰, Gabriel Daniel Duda¹¹, and Ahmed Omar Kaseb¹²

¹Radiology, MD Anderson, Houston, TX, United States, ²Interventional Radiology, MD Anderson, Houston, TX, United States, ³Imaging Physics, MD Anderson, Houston, TX, United States, ⁴Cancer Systems Imaging, MD Anderson, Houston, TX, United States, ⁵Biostatistics, MD Anderson, Houston, TX, United States, ⁶GI Medical Oncology, MD Anderson, Houston, TX, United States, ⁷Epidemiology, MD Anderson, Houston, TX, United States, ⁸Hemopathology, MD Anderson, Houston, TX, United States, ⁹Pathology, MD Anderson, Houston, TX, United States, ¹⁰Radiology, Mayo Clinic, Rochester, MN, United States, ¹¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States, ¹²MD Anderson, Houston, TX, United States

Newer systemic treatments for advanced hepatocellular carcinoma (HCC) include immune checkpoint blockade (ICB) which act through increasing cytotoxic T-cell mediated response to tumor. There is a lack of biomarkers of ICB response and treatment outcomes are not correlated with change in tumor size. We evaluated MRI imaging features of HCC and change in tumor stiffness after 6 weeks immunotherapy in surgical and non-surgical patients. An increase in HCC stiffness on MRE after 6 weeks treatment was significantly correlated with treatment response. Longitudinal measurement of tumor stiffness on MRE provides a novel technique for early immunotherapy response assessment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here